After months of meticulous work, your cells suddenly behave unpredictably, or your mouse models develop fever and systemic inflammation during critical studies. The hidden culprit may be endotoxin, ...
The 2026 Government Work Report identified biopharmaceuticals as an emerging pillar industry for the first time, placing it ...
PDUFA target action date of November 14, 2026 Potential first FDA-approved treatment option for the acute treatment of ...
Preclinical research on Caliway's fat reduction drug candidate CBL-514 in combination with GLP-1R-based weight-loss therapies has been selected for presentation at the American Diabetes Association's ...
HCW Biologics Inc. (the 'Company” or 'HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing ...
Teva’s biosimilar, PONLIMSI™, is now FDA-approved across all indications of the reference product, Prolia ® (denosumab), to treat a variety of ...
NJ Bio, Inc. (NJ Bio), a leading provider of integrated drug discovery and development services and Ajinomoto Bio‑Pharma ...
Respondents to a survey note an urgent need for role-specific training to bridge knowledge gaps in advanced-therapy ...
Closed upsized initial public offering in February 2026, raising $381 million in gross proceedsCompleted enrollment of the TeLuRide-005 Phase 2 ...
French pharmaceutical and dermo-cosmetics company Pierre Fabre Laboratories will continue to increase its investment and ...
The report is available on the SEC’s website, at www.sec.gov and Galmed’s Investor Relations website, at https://galmedpharma.investorroom.com/sec-filings.
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“Acurx” or the “Company”), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult‑to‑treat bacterial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results